Gapping up
M&A news:
- ATV +32.7% (enters merger agreement for going private transaction for $21.00 per ADS)
- LMPX +20.3% (LMP Automotive to acquire a 70% Interest in New York's largest franchise dealership group)
- DOYU+14.3% (HUYA (HUYA) and DouYu (DOYU) enter stock-for-stock merger agreement)
- TWLO +6.9% (acquires Segment for approximately $3.2 billion in Twilio Class A common stock, on a fully diluted and cash free, debt free basis)
Other news:
- LIZI +61.1% (has been selected into first 10 Guangdong-based online audiovisual companies to participate in a local government-backed pilot program)
- ALKS +12.7% (announces positive voting outcomes from FDA committee meetings)
- EYEN +9.7% (Eyenovia and Bausch Health Companies (BHC) reach licensing agreement for Eyenovia's investigational treatment for the reduction of pediatric myopia progression in children)
- AKBA +8.7% (to Present Global Phase 3 Vadadustat Data at American Society of Nephrology Kidney Week 2020 Reimagined)
- ALT +3.5% (Altimmune and UAB report publication of pre-clinical data for AdCOVID intranasal COVID-19 vaccine candidate)
- RTRX +3.2% (announces presentation of abstracts at ASN Kidney Week 2020 Reimagined)
- AAPL +3.2% (co is starting to use its retail stores as distribution centers for shipping products to consumers, according to Bloomberg)
- CEIX +2.6% (provided an update on several transactions that were executed during the last several months)
- APAM +1.9% (provides Sep AUM data)
- VEEV +1.7% (provides highlights ahead of Veeva R&D and Quality Summit October 13-14, 2020)
- BHC +1.2% (Eyenovia and Bausch Health Companies (BHC) reach licensing agreement for Eyenovia's investigational treatment for the reduction of pediatric myopia progression in children)
- TAK +1.1% (reports safety and efficacy data for subcutaneous Entyvio)
Analyst comments:
- TAST +5.4% (upgraded to Outperform from Mkt Perform at Raymond James)
- TWTR +4.6% (upgraded to Buy from Hold at Deutsche Bank)
- DKNG +3% (initiated with an Outperform at Credit Suisse)
- IP +2.6% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- WRK +2.1% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- PEP +1.6% (upgraded to Buy from Neutral at Citigroup)
- PKG +1.1% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- CB +1% (upgraded to Overweight from Neutral at JP Morgan)
- F +1% (upgraded to Buy from Hold at The Benchmark Company)